DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Sikov WM, Berry DA, Perou CM et al.
Impact of the addition of carboplatin and/or Bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
J Clin Oncol 2015;
33: 13-21
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.